Thirumalai Chemicals to Raise ₹400–500 Crore via Preference Issue and Non-Core Asset Sale

Market snapshot: Thirumalai Chemicals is planning to raise ₹400–500 crore through a combination of a preference share issuance and the monetization of non-core assets to address liquidity pressures and fund ongoing debt obligations. This capital-raising effort comes amid a widening liquidity gap at the consolidated level, driven primarily by cost overruns at its US expansion project. The company intends to execute a preference share issue of ₹200–250 crore as part of this broader fundraising plan.

Data Snapshot

• The company is planning a ₹200–250 crore preference share issuance to raise immediate capital.
• The Board of Directors approved raising up to ₹750 crore through debt and/or equity instruments, including a possible QIP, to manage day-to-day operations and debt refinancing.
• To strengthen short-term liquidity, the Board approved the sale of four windmills in Tamil Nadu for ₹10.35 crore to TN Oxygen Private Limited.
• Consolidated current liabilities exceed current assets by ₹742.12 crore, while standalone current liabilities exceed current assets by ₹325.28 crore as of June 30, 2026.

What's Changed

• Consolidated net loss narrowed to ₹43.67 crore in Q1 FY27, compared to a net loss of ₹60.00 crore in Q1 FY26.
• Standalone net profit turned positive at ₹14.21 crore in Q1 FY27, marking a turnaround from the standalone loss of ₹13.80 crore in Q1 FY26.
• Consolidated revenue increased by 21.47% YoY to ₹546.67 crore from ₹450.10 crore in Q1 FY26.
• Consolidated EBITDA turned positive at ₹35.90 crore in Q1 FY27 (EBITDA margin of 6.6%), reversing the EBITDA loss of ₹24.50 crore in Q1 FY26.

Key Takeaways

• Standalone core operations have achieved profitability, showing operational resilience with an standalone Q1 FY27 PAT of ₹14.21 crore.
• Consolidated finances are heavily dragged down by capital expenditure for the US subsidiary, TCL Specialties LLC, which is experiencing construction delays and cost overruns.
• High short-term debt and working capital mismatch has resulted in current liabilities exceeding current assets by ₹742.12 crore.
• Credit rating revision to BBB (Negative) by ICRA on August 13, 2026 reflects elevated liquidity stress and US project cost escalations to US$ 340 million.

SAHI Perspective

While the turnaround in standalone operations is encouraging, consolidated performance is tightly bound to the capital-heavy US expansion. Pushing back the US subsidiary's commercial launch to December 2026 has locked up essential liquidity, forcing defensive fundraising of up to ₹500 crore. The preference issue and windmill divestment are strictly survival tools meant to support high near-term debt servicing. Investors must caution against assuming immediate growth, as financial stress will persist until the US project starts operations and successfully refinances its debt.

Market Implications

The planned capital raise will likely prevent immediate default but will keep interest costs high, suppressing consolidated earnings. The market response will remain muted as positive standalone results are overshadowed by the credit rating downgrade and the structural liquidity deficit.

Trading Signals

Market Bias: Bearish

Despite Q1 FY27 standalone net profit turning positive at ₹14.21 crore, the stock is structurally pressured by a massive consolidated working capital gap of ₹742.12 crore, credit rating downgrades to BBB (Negative) by ICRA, and US project cost escalations to US$ 340 million.

Overweight: Commodity Chemicals

Underweight: Highly Leveraged Commodity Chemical Manufacturers

Trigger Factors:

• Successful execution of the planned ₹200–250 crore preference share issue.
• Commissioning of the US plant in December 2026 without further cost escalation.
• Refinancing of the US$ 130–180 million debt facility for the US subsidiary.

Time Horizon: Near-term (0-3 months)

Industry Context

The commodity chemicals sector in India is highly cyclical and vulnerable to feedstock cost fluctuations and global import pricing. For a leading producer of phthalic anhydride and malic acid like Thirumalai Chemicals, maintaining stable margins is challenging. High capital expenditure in foreign geographies without immediate revenue generation severely stretches the balance sheets of mid-sized Indian chemical manufacturers.

Key Risks to Watch

• US Expansion Delay: Further extension of the TCL Specialties LLC commercial launch past December 2026.
• Refinancing Risk: Failure to finalize the US$ 130–180 million debt facility or the domestic ₹750 crore raise.
• Regulatory Liabilities: Adverse outcome from the ₹22.93 crore GST show cause notice received on July 30, 2026.

Recent Developments

On August 13, 2026, ICRA downgraded Thirumalai Chemicals' long-term ratings to [ICRA]BBB (Negative) from [ICRA]BBB+ (Negative), citing liquidity stress and US project cost escalations to US$ 340 million. Separately, on July 30, 2026, the company received a show cause notice from the Ranipet GST department demanding ₹22.93 crore in unpaid taxes and dues for FY23.

Closing Insight

Thirumalai Chemicals' core Indian business is highly profitable, but the group is heavily constrained by its debt-heavy US expansion. Refinancing execution remains the single most critical monitorable for survival.

High Performance Trading with SAHI.